Clinical Trial Update: Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD) [Phase 2]

View source ↗

Summary

Phase 2 open-label extension trial update for AOC 1020 in facioscapulohumeral muscular dystrophy (FSHD) by Avidity Biosciences; enrollment is ongoing by invitat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy

Drugs mentioned

• AOC 1020

Snippet

Sponsor: Avidity Biosciences, Inc. | Conditions: FSHD, FSHD1 | Phase 2 | Status: ENROLLING_BY_INVITATION